No results found for "".

Commentary & Deal Flow

RATED: Mdys/S&P/Fitch rate CAB sr sec B2/B-/B+, Laboratoire Eimer sr notes Caa1/CCC/CCC+

HYC European Market: Deal Flow - General

Moody's/S&P/Fitch rate Biogroup EUR1bn 144A/Reg S 2-part - CAB EUR750m sr sec notes due 2028 (7y) B2/B-/B+ (negative/stable/stable); and Laboratoire Eimer EUR250m sr notes due 2029 (8y) Caa1/CCC/CCC+ (negative/stable/stable). Via JPM+. Fitch also revised the outlook to stable from negative